It would be nice to have a cheap treatment for everyone infected to keep the disease from becoming severe. An easy to administer, low cost treatment (cheap pill) with few side effects (maybe not such a clean safety profile for fluvoxamine?) is probably the best way to go.
Unfortunately, the absolute risk reduction in higher risk people was only around 4% (14.7% to 10.4%), so the number of people needed to treat to keep one person out of the hospital was 24.
As you said, I doubt that (1) enough people will take something like this, and (2) even for those that do, there still will be a large number (10%+) that go on to require hospitalization.
That is where brilacidin could find its niche for IV infusion over 5 days.
News 
Market Data 
Discover 
AI
